InvestorsHub Logo
Followers 36
Posts 1166
Boards Moderated 0
Alias Born 03/07/2013

Re: LaddyMan post# 23610

Wednesday, 01/13/2016 1:22:35 PM

Wednesday, January 13, 2016 1:22:35 PM

Post# of 118380
In spite of the dilutive shares, I still see good things ahead for 2016 and the company overall is still in a much better situation than Jan 1, 2015, before all the changes started.

1. In 2015 we went from 50M initial shares to 124M OS shares or an increase of 74M shares (30M was to "angel investors"). According to today's letter, the time for more of those undervalued shares is now limited and I think today's letter to start off 2016 was purposeful and meant to create a new tone. So hopefully we don't see more than 30M-40M max of new highly undervalued shares.

2. Q2 IND for NR2F6 - this actually just struck me that this is significant because unlike HemaX and dCellVax, NR2F6 compound testing is now being done by NIH and any formula/compound that they come up with or verify against the 2 compound lists at NCATS has this reality: NR2F6 IND testing will have been performed at GLP lab with compounds already deemed safe for use in humans, i.e. NR2F6 could move quickly forward towards FDA approval and clinical trials without the delays incurred by HemaX and dCellVax!

3. Q2 IND dCellVax response is being prepped by Dr. Santoosh Kesari at John Wayne Cancer Research Center, so that response and experimental data should meet FDA requirements as well. Which means RGBP could have 2 FDA approved products for clinical trials by Q2 and a third IND submitted with possible data from NIH/NCATS for FDA approval. That means last year's Jan 2015 contract with C. Ichim was very realistic in having incentive shares regarding 3 INDs and 3 relationships with outside CROs.

As disappointing as the PPS movement has been, the more I put into perspective what may realistically happen in 2016 and how that will position the company vs. where we were in 2014, it is night and day and as long as Lander follows through with establishing funding and relationships that don't undermine or undervalue the current share price, we should end 2016 much higher than we are now.

We are on much better grounds - it's just going to take time to walk to higher ground. I'm feeling much better about the letter and the chances of success in the future have only increased, not decreased over the past several months.